Taken together, these results support the argument that a hyperactivated CK2–HTATSF1–TOPBP1 axis confers poor responsiveness of breast tumors to chemotherapeutic agents and that loss of HTATSF1 renders breast tumors more vulnerable to cisplatin treatment. Here, TOPBP1 is linked to breast neoplasm.